Kymera Therapeutics Inc. has disclosed signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders, cardiovascular disorders, viral infections, neurodegeneration, and autoimmune, metabolic and liver diseases, among others.